Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
A Study of TYRA-300 in Children With Achondroplasia: BEACH301
NCT06842355 · View on ClinicalTrials.gov ↗
Study Summary
The purpose of this study is to evaluate the safety, tolerability, and identify potentially effective dose(s) of TYRA-300 in children with achondroplasia with open growth plates.
Conditions Studied
Interventions
- DRUG TYRA-300 0.125 mg/kg
- DRUG TYRA-300 0.25 mg/kg
- DRUG TYRA-300 0.375 mg/kg
- DRUG TYRA-300 0.50 mg/kg
Study Locations (13)
Maryland
- Johns Hopkins University School of Medicine — Baltimore
- Uncommon Cures — Chevy Chase
Missouri
- University of Missouri — Columbia
- Washington University — St Louis
California
- Lundquist Institute for Biomedical Innovation — Torrance
Colorado
- Children's Hospital Colorado — Aurora
Delaware
- Nemours Alfred I duPont Hospital for Children — Wilmington
Tennessee
- Vanderbilt University Medical Center — Nashville
Texas
- Children's Medical Center, Dallas — Dallas
Wisconsin
- University of Wisconsin-Madison — Madison
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 92 participants |
| Start Date | 2025-03-04 |
| Est. Completion | 2030-06 |
| Phase | Phase 2 |
Interested in This Trial?
Always speak with your doctor before enrolling in a clinical trial.
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06842355
The ClinicalTrials.gov registry entry for NCT06842355 describes a study currently listed as recruiting. It is categorized as Phase 2, which is the standard way researchers label where a study sits along the investigational pathway from early safety work through later efficacy and post-marketing evaluation. The registered enrollment target is 92 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Tyra Biosciences, which has 6 total studies on file at ClinicalTrials.gov, and sponsors are the parties responsible for study design, oversight, and regulatory filings.
The record links to 1 condition, with Achondroplasia appearing as the primary indexed condition, and to 4 interventions — of which TYRA-300 0.125 mg/kg is the first listed. Interventions can include drugs, devices, procedures, behavioral programs, or observational arms, and each is tracked as a separate registry field so that downstream queries can filter accurately. When a trial lists multiple interventions, it usually reflects a multi-arm design or a comparison protocol rather than a single treatment being tested in isolation. The brief summary published in the registry is the clearest source of protocol intent and should be read before drawing conclusions from any sidebar tags.
Geographic footprint matters for practical reasons: NCT06842355 reports 13 study locations spanning 11 distinct geographic areas — top geographies include Maryland, Missouri, California. A larger site network tends to correlate with broader recruitment capacity, but it does not imply anything about study quality, and site-level enrollment status can diverge from the overall registry status shown above. Every data point on this page comes from the public ClinicalTrials.gov dataset and is reproduced here for reference only; it is not a medical recommendation, an endorsement of the sponsor, or an invitation to enroll. Verify current status, eligibility criteria, and contact details directly at ClinicalTrials.gov, and discuss any participation decision with your own healthcare provider.
Frequently Asked Questions
What is clinical trial NCT06842355 about?
NCT06842355 is a clinical study titled "A Study of TYRA-300 in Children With Achondroplasia: BEACH301". The purpose of this study is to evaluate the safety, tolerability, and identify potentially effective dose(s) of TYRA-300 in children with achondroplasia with open growth plates.
What is the current status of trial NCT06842355?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 92 participants. The study started on 2025-03-04. Estimated completion is 2030-06.
What conditions does trial NCT06842355 study?
This clinical trial studies the following conditions: Achondroplasia. These conditions were identified from the trial registry and reflect the primary focus areas of the research.
What interventions are being tested in trial NCT06842355?
The interventions under investigation include: TYRA-300 0.125 mg/kg (DRUG), TYRA-300 0.25 mg/kg (DRUG), TYRA-300 0.375 mg/kg (DRUG), TYRA-300 0.50 mg/kg (DRUG). Each intervention is being evaluated for safety and efficacy as part of this clinical study.
Who is sponsoring clinical trial NCT06842355?
This trial is sponsored by Tyra Biosciences, which has 6 total clinical trials registered on ClinicalTrials.gov. The sponsor is responsible for the study's design, funding, and regulatory compliance.
Where is trial NCT06842355 being conducted?
This trial has 13 study locations across California, Colorado, Delaware, Maryland, Missouri. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How Clinical Trials Work
Understand phases 1-4, trial design, randomization, and the informed consent process.
Patient Rights in Clinical Trials
Your rights as a participant: consent, withdrawal, privacy, and who to contact.
Finding the Right Clinical Trial
A practical guide to searching trials, understanding eligibility, and evaluating options.
All Guides
Browse our complete library of clinical trial educational resources.
Read our methodology — how this data is sourced, computed, and verified.